Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: topvest who wrote (674)	7/18/1998 8:28:00 PM
From: l. euler	Read Replies (2) \| Respond to of 849

topvest - It's good to hear from you again! After reading the article you mentioned, I got a sinking feeling. I thought that, at a minimum, this company had a future with NMP22 sales. It seems, though, that perhaps the ability of the NMP22 isn't as great as I once believed. This is very serious, and I hope that the company counters with independent studies of its own. Otherwise, I think that FDA approval for the NMP22 as a screening test is doomed. When the stock dropped below $2, I wrote Chubb a message telling him that either the market was wrong in its valuations or my assumptions about the company's potential were wrong (he responded with some nonsense that he had a lot of shares too. Unfortunately, he controls the company, not me). But you're right: If other officers aren't buying at these prices then that validates the $2.25 market price. Perhaps, my assumptions about Matritech's potential are indeed wrong. Say it isn't so! l. euler